-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China

PUBT·11/06/2026 11:10:55
Listen to the news
CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China
  • CSPC Pharmaceutical Group announced November 6, 2026, the initiation of a Phase I/II SYS6055 trial for relapsed/refractory B-cell non-Hodgkin lymphoma in China.
  • The SYS6055-003 study is recruiting participants following Chinese regulatory clearance in October 2026 to assess safety, drug behavior and preliminary efficacy.
  • SYS6055 generates CD19-targeting CAR-T cells directly inside the body, offering potential advantages in treatment cost, access and speed over traditional CAR-T products.
  • Previously disclosed findings from an ongoing Phase I/II trial in relapsed/refractory aggressive B-cell lymphoma showed favorable safety and preliminary signs of efficacy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261106-12404310), on November 06, 2026, and is solely responsible for the information contained therein.